Cel Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack of specific targeting nature of current treatments. Nanomedicine can reduce such side-effects by exploiting characteristic properties of tumors for targeted delivery and therapy. Despite extensive research, most nanomedicines developed so far have relied on passive targeting using a single therapeutic modality, which are inefficient for treatment of challenging conditions such as multi-drug resistance.Recently we developed a pH-responsive-DNA-GNP conjugate based nanocarrier that numerous features required for an ideal drug nanocarrier, e.g. uniform small nanoscale size, resisting non-specific adsorption, non-toxic, biocompatible, water-soluble, stable, and having high drug loading and controlled release capacities. It can offer efficient and pH-triggered drug release suitable for effective cancer chemotherapy at the cellular level using doxorubicin, a widely used chemotherapy drug.Herein we will extend it into a more effective, multifunctional nanomedicine that can offer simultaneous biomodal chemotherapies with hyperthermia and MRI imaging capacities. First, we will prepare, characterize, and evaluate their drug loading & release profiles in buffer; then we will study and quantify their cell- & cell-specific- uptake and drug delivery efficiency, and then evaluate their toxicity, cytotoxicity & cell-specific cytotoxicity with cancer cells (incoming phase), and finally evaluate their synergistic therapeutic efficacy at cellular and preclinical level (re-integration phase). This project will greatly benefit both the fundamental research in nanomedicine and the healthcare/pharmaceutical indurstries in Europe. Dziedzina nauki medical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncologyengineering and technologynanotechnologynano-materialsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Program(-y) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Temat(-y) FP7-PEOPLE-2012-IIF - Marie Curie Action: "International Incoming Fellowships" Zaproszenie do składania wniosków FP7-PEOPLE-2012-IIF Zobacz inne projekty w ramach tego zaproszenia System finansowania MC-IIF - International Incoming Fellowships (IIF) Koordynator UNIVERSITY OF LEEDS Wkład UE € 309 235,20 Adres WOODHOUSE LANE LS2 9JT Leeds Zjednoczone Królestwo Zobacz na mapie Region Yorkshire and the Humber West Yorkshire Leeds Rodzaj działalności Higher or Secondary Education Establishments Kontakt administracyjny Martin Hamilton (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych
